Biotech Values

[DewDiligence]

GTCB (from SI):

>>
From: DewDiligence_on_SI
6/2/2006 2:30:43 PM
To: Sam Citron who wrote (2517) of 2518

> How do you see this news impacting chance for US approval?<

The U.S. ATryn program figures to be an easier sell to the regulators for two reasons:

1. The U.S. phase-3 trial is larger and contains a control arm.

2. The unmet medical need in the U.S. is greater because (unlike Europe) plasma-derived antithrombin is rarely available in the U.S.

I think the probability of FDA approval for ATryn in 2008 is about 85%. Regards, Dew
<<